Standard BioTools Inc. (LAB)
USD 1.99
(-10.18%)
USD 1.99
(-10.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 46.5 Million USD | 117.87% |
| 2022 | 21.34 Million USD | -74.34% |
| 2021 | 83.19 Million USD | 209.8% |
| 2020 | 26.85 Million USD | -29.91% |
| 2019 | 38.31 Million USD | -50.02% |
| 2018 | 76.65 Million USD | -44.12% |
| 2017 | 137.18 Million USD | -14.21% |
| 2016 | 159.9 Million USD | -4.0% |
| 2015 | 166.56 Million USD | 2.98% |
| 2014 | 161.74 Million USD | 558.7% |
| 2013 | -35.26 Million USD | 39.88% |
| 2012 | -58.64 Million USD | -1617.39% |
| 2011 | -3.41 Million USD | -128.22% |
| 2010 | 12.1 Million USD | 8682.98% |
| 2009 | -141 Thousand USD | 94.54% |
| 2008 | -2.58 Million USD | 86.9% |
| 2007 | -19.71 Million USD | -2310.54% |
| 2006 | 892 Thousand USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -179.26 Million USD | 8.15% |
| 2024 Q3 | -121.17 Million USD | 32.4% |
| 2024 Q1 | -195.16 Million USD | -519.64% |
| 2023 Q1 | -11.68 Million USD | -154.72% |
| 2023 Q2 | -40.91 Million USD | -250.28% |
| 2023 Q3 | 20.06 Million USD | 149.04% |
| 2023 Q4 | 46.5 Million USD | 131.78% |
| 2023 FY | 46.5 Million USD | 117.87% |
| 2022 Q4 | 21.34 Million USD | -50.24% |
| 2022 Q3 | 42.9 Million USD | 46.87% |
| 2022 FY | 21.34 Million USD | -74.34% |
| 2022 Q1 | 110.01 Million USD | 32.24% |
| 2022 Q2 | 29.21 Million USD | -73.45% |
| 2021 Q3 | 75.77 Million USD | 16.38% |
| 2021 Q2 | 65.11 Million USD | 46.2% |
| 2021 FY | 83.19 Million USD | 209.8% |
| 2021 Q4 | 83.19 Million USD | 9.79% |
| 2021 Q1 | 44.53 Million USD | 65.84% |
| 2020 Q1 | 59.72 Million USD | 55.87% |
| 2020 Q3 | 23.08 Million USD | -55.92% |
| 2020 Q4 | 26.85 Million USD | 16.36% |
| 2020 FY | 26.85 Million USD | -29.91% |
| 2020 Q2 | 52.35 Million USD | -12.34% |
| 2019 FY | 38.31 Million USD | -50.02% |
| 2019 Q1 | -6.94 Million USD | -109.06% |
| 2019 Q2 | 33.94 Million USD | 588.62% |
| 2019 Q3 | 30.78 Million USD | -9.31% |
| 2019 Q4 | 38.31 Million USD | 24.45% |
| 2018 Q3 | 133.51 Million USD | 4.85% |
| 2018 Q4 | 76.65 Million USD | -42.59% |
| 2018 Q2 | 127.33 Million USD | 4.21% |
| 2018 Q1 | 122.18 Million USD | -10.93% |
| 2018 FY | 76.65 Million USD | -44.12% |
| 2017 Q4 | 137.18 Million USD | 2.21% |
| 2017 FY | 137.18 Million USD | -14.21% |
| 2017 Q3 | 134.22 Million USD | -13.68% |
| 2017 Q2 | 155.49 Million USD | 3.03% |
| 2017 Q1 | 150.92 Million USD | -5.62% |
| 2016 Q4 | 159.9 Million USD | -1.64% |
| 2016 FY | 159.9 Million USD | -4.0% |
| 2016 Q3 | 162.57 Million USD | 2.3% |
| 2016 Q2 | 158.91 Million USD | 4.63% |
| 2016 Q1 | 151.88 Million USD | -8.81% |
| 2015 Q1 | 158.53 Million USD | -1.99% |
| 2015 FY | 166.56 Million USD | 2.98% |
| 2015 Q4 | 166.56 Million USD | -0.15% |
| 2015 Q3 | 166.8 Million USD | -2.92% |
| 2015 Q2 | 171.82 Million USD | 8.39% |
| 2014 Q2 | 151.66 Million USD | 60.96% |
| 2014 Q3 | 164.46 Million USD | 8.44% |
| 2014 Q4 | 161.74 Million USD | -1.65% |
| 2014 Q1 | 94.22 Million USD | 367.22% |
| 2014 FY | 161.74 Million USD | 558.7% |
| 2013 Q4 | -35.26 Million USD | -75.44% |
| 2013 FY | -35.26 Million USD | 39.88% |
| 2013 Q3 | -20.09 Million USD | 37.75% |
| 2013 Q1 | -61.81 Million USD | -5.4% |
| 2013 Q2 | -32.29 Million USD | 47.76% |
| 2012 Q2 | -5.15 Million USD | -139.25% |
| 2012 FY | -58.64 Million USD | -1617.39% |
| 2012 Q4 | -58.64 Million USD | 8.56% |
| 2012 Q1 | -2.15 Million USD | 36.95% |
| 2012 Q3 | -64.13 Million USD | -1145.12% |
| 2011 FY | -3.41 Million USD | -128.22% |
| 2011 Q1 | -41.49 Million USD | -442.86% |
| 2011 Q2 | 2.87 Million USD | 106.93% |
| 2011 Q3 | -291 Thousand USD | -110.11% |
| 2011 Q4 | -3.41 Million USD | -1073.54% |
| 2010 Q3 | 9.52 Million USD | 0.0% |
| 2010 FY | 12.1 Million USD | 8682.98% |
| 2010 Q4 | 12.1 Million USD | 27.03% |
| 2009 Q4 | -141 Thousand USD | 0.0% |
| 2009 FY | -141 Thousand USD | 94.54% |
| 2008 FY | -2.58 Million USD | 86.9% |
| 2008 Q4 | -2.58 Million USD | 0.0% |
| 2008 Q2 | -12.4 Million USD | 0.0% |
| 2007 FY | -19.71 Million USD | -2310.54% |
| 2007 Q4 | -19.71 Million USD | 0.0% |
| 2006 FY | 892 Thousand USD | 0.0% |
| 2001 Q3 | -2.35 Million USD | 0.0% |
| 2001 Q4 | 66.31 Million USD | 2913.32% |
| 2001 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bionano Genomics, Inc. | 34.88 Million USD | -33.324% |
| Prenetics Global Limited | -43.33 Million USD | 207.312% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 403.227% |
| CareDx, Inc | -47.97 Million USD | 196.936% |
| Exact Sciences Corporation | 1.94 Billion USD | 97.614% |
| Exagen Inc. | -12.77 Million USD | 464.125% |
| Inotiv, Inc. | 382.14 Million USD | 87.83% |
| Guardant Health, Inc. | 220.22 Million USD | 78.883% |
| Biodesix, Inc. | 34.3 Million USD | -35.558% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 902.389% |
| Precipio, Inc. | -386 Thousand USD | 12148.187% |
| iSpecimen Inc. | -2.14 Million USD | 2265.667% |
| Natera, Inc. | -200.1 Million USD | 123.241% |
| Aspira Women's Health Inc. | -331 Thousand USD | 14150.151% |
| 23andMe Holding Co. | -141.37 Million USD | 132.896% |
| Castle Biosciences, Inc. | -83.53 Million USD | 155.675% |
| Personalis, Inc. | -8.02 Million USD | 679.731% |
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 217.88% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 886.366% |
| OpGen, Inc. | 11.89 Million USD | -291.073% |
| T2 Biosystems, Inc. | 33.8 Million USD | -37.555% |
| Myriad Genetics, Inc. | 88.1 Million USD | 47.212% |
| ICON Public Limited Company | 3.56 Billion USD | 98.694% |
| NeoGenomics, Inc. | 269.19 Million USD | 82.724% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 403.227% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 90.585% |
| RadNet, Inc. | 1.14 Billion USD | 95.951% |
| MDxHealth SA | 18.88 Million USD | -146.259% |
| Psychemedics Corporation | 334 Thousand USD | -13823.952% |
| Illumina, Inc. | 1.21 Billion USD | 96.169% |
| Check-Cap Ltd. | -24.75 Million USD | 287.857% |
| Twist Bioscience Corporation | -192.4 Million USD | 124.171% |
| DarioHealth Corp. | -7.54 Million USD | 716.137% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 156.326% |
| Sera Prognostics, Inc. | -2.02 Million USD | 2400.0% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 2006.371% |
| OPKO Health, Inc. | 230.68 Million USD | 79.84% |
| Medpace Holdings, Inc. | -103.32 Million USD | 145.009% |
| Neogen Corporation | 735.62 Million USD | 93.678% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 956.045% |
| Prenetics Global Limited | -43.33 Million USD | 207.312% |
| Mainz Biomed B.V. | 349.85 Thousand USD | -13192.936% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 3841.64% |
| Trinity Biotech plc | 63.73 Million USD | 27.033% |
| Neuronetics, Inc. | 2.79 Million USD | -1562.71% |
| Sotera Health Company | 2.02 Billion USD | 97.704% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 3841.64% |